Thomas Malley

Thomas Malley, listed as board member, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Kiniksa Pharmaceuticals International, plc, BeOne Medicines Ltd. and Kura Oncology, Inc. Over a trading history stretching from 31 December 2015 to 18 March 2026, the count stands at 10 filings.

No open-market sale appears; the market trades are 1 purchase worth €525k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 4 share grants and 5 option exercises.

The record was last updated on 20 March 2026 with an option exercise (€27k) in Kura Oncology, Inc. The latest purchase dates back some time: it was published 1,215 days ago, on 21 June 2023. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.